Pharma Pioneer

Kazia Therapeutics Announces Successful Endpoint in Phase I Trial

24 May 2024
3 min read

On February 21, 2024, Kazia Therapeutics Limited, an Australian biotech firm listed on NASDAQ (KZIA), announced the premature completion of a Phase I clinical trial due to favorable safety outcomes and clinical responses. The study focused on the use of paxalisib, an oral medication that inhibits both PI3K and mTOR, alongside radiation therapy for patients with brain metastases from solid tumors that have a PI3K pathway mutation.

The first part of the trial determined the maximum tolerated dose (MTD) of paxalisib when combined with radiation and showed potential clinical benefits in all nine patients assessed. The second part expanded the cohort to further study the MTD's safety and efficacy in up to 12 more patients. Preliminary results from Part II showed that the study's primary endpoint was met, with continued positive clinical responses observed.

Kazia's CEO, Dr. John Friend, expressed optimism regarding the results, which indicate both safety and potential effectiveness of paxalisib combined with radiation therapy. The company plans to consult with the FDA to discuss the findings and seek guidance for a pivotal study to further the development of paxalisib as a more effective treatment for brain metastases.

Research has indicated that the PI3K pathway is often activated in brain metastases, potentially causing resistance to radiation treatment. This provides a rationale for combining paxalisib with radiation therapy to enhance the sensitivity of tumor cells to radiation. Paxalisib received Fast Track Designation from the FDA in the previous year based on the initial clinical data for treating brain metastases with PI3K pathway mutations.

In the United States, around 200,000 cancer patients develop brain metastases annually, with radiotherapy being the primary treatment method. However, the effectiveness of whole brain radiotherapy (WBRT) varies, and the need for new treatment options is evident due to the increasing prevalence and low response rates to current treatments.

Kazia Therapeutics is also developing EVT801, a VEGFR3 inhibitor, which has shown activity against various tumor types and potential synergy with immuno-oncology drugs. A Phase I study for EVT801 is underway, with preliminary data expected in 2024.

The company's lead product, paxalisib, has received several designations from the FDA, including Orphan Drug Designation for glioblastoma and Fast Track Designation for specific brain cancer treatments. 

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Lutris Pharma Reports Positive Phase 1/2 Results for LUT014 in Breast Cancer Radiation Dermatitis
Pharma Pioneer
2 min read
Lutris Pharma Reports Positive Phase 1/2 Results for LUT014 in Breast Cancer Radiation Dermatitis
24 May 2024
Lutris Pharma has published positive results from a phase 1/2 clinical trial of their lead compound, LUT014.
Read →
Sairiyo Therapeutics, a PharmaTher Subsidiary, Commences Phase 1 Trial for Patented Cepharanthine in Australia
Pharma Pioneer
2 min read
Sairiyo Therapeutics, a PharmaTher Subsidiary, Commences Phase 1 Trial for Patented Cepharanthine in Australia
24 May 2024
Sairiyo Therapeutics Inc., has begun regulatory and clinical development to assess the potential of its patented enteric-coated cepharanthine (PD-001) for treating oncology and infectious diseases.
Read →
Pharma Frontiers: Daily Digest of Global Pharmaceutical News - May 23
Pharma Frontiers
11 min read
Pharma Frontiers: Daily Digest of Global Pharmaceutical News - May 23
23 May 2024
May 23rd latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
Read →
Ionis reveals favorable topline outcomes from Phase 1/2a study of ION582 for Angelman syndrome
Latest Hotspot
4 min read
Ionis reveals favorable topline outcomes from Phase 1/2a study of ION582 for Angelman syndrome
23 May 2024
Ionis Pharmaceuticals, Inc. reported favorable primary results from the HALOS Phase 1/2a open-label trial of ION582 for Angelman syndrome.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.